SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2012
SUBSEQUENT EVENTS	NOTE 12 – SUBSEQUENT EVENTS (a) Medivation Equity Incentive Plan In July 2012, the Company’s stockholders approved an amendment to the Medivation Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the Plan by 1,800,000 shares and to approve the Plan’s performance criteria and award limits. As a result, in the third quarter of 2012, the Company’s outstanding cash-settled stock appreciation rights have been converted to stock-settled stock appreciation rights. (b) Development Milestone Payment Under Astellas Collaboration Agreement In July 2012, the FDA accepted for filing the New Drug Application, or NDA, for enzalutamide for the potential treatment of post-chemotherapy advanced prostate cancer and granted priority review designation. The FDA’s acceptance for filing of the NDA triggers a $10.0 million development milestone payment to the Company under the Astellas Collaboration Agreement, which the Company expects to recognize as collaboration revenue during the third quarter of 2012. The Company is required to share 10% of the milestone payment with UCLA pursuant to the terms of its enzalutamide license agreement, which will be recorded as research and development expense.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2012

NOTE 12 – SUBSEQUENT EVENTS

(a) Medivation Equity Incentive Plan

In July 2012, the Company’s stockholders approved an amendment to the Medivation Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the Plan by 1,800,000 shares and to approve the Plan’s performance criteria and award limits. As a result, in the third quarter of 2012, the Company’s outstanding cash-settled stock appreciation rights have been converted to stock-settled stock appreciation rights.

(b) Development Milestone Payment Under Astellas Collaboration Agreement

In July 2012, the FDA accepted for filing the New Drug Application, or NDA, for enzalutamide for the potential treatment of post-chemotherapy advanced prostate cancer and granted priority review designation. The FDA’s acceptance for filing of the NDA triggers a $10.0 million development milestone payment to the Company under the Astellas Collaboration Agreement, which the Company expects to recognize as collaboration revenue during the third quarter of 2012. The Company is required to share 10% of the milestone payment with UCLA pursuant to the terms of its enzalutamide license agreement, which will be recorded as research and development expense.